Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas

Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas

Abstract Background The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitors (DPP4i) are hypoglycaemic agents licensed for the treatment of type 2 diabetes mellitus (T2DM). Although these drugs possess comparable efficacy and low risk of hypoglycaemia, differences in...

Full description

Bibliographic Details
Main Authors: Giuseppe Roberto, Francesco Barone-Adesi, Francesco Giorgianni, Valeria Pizzimenti, Carmen Ferrajolo, Michele Tari, Claudia Bartolini, Roberto Da Cas, Marina Maggini, Stefania Spila-Alegiani, Paolo Francesconi, Gianluca Trifirò, Elisabetta Poluzzi, Fabio Baccetti, Rosa Gini
Format: Article
Language:English
Published: BMC 2019-02-01
Series:BMC Endocrine Disorders
Subjects:
Glucagon-like peptide-1 analogues
Dipeptidyl peptidase-4 inhibitors
Drug utilization
Database network
Online Access:http://link.springer.com/article/10.1186/s12902-019-0334-y

Internet

http://link.springer.com/article/10.1186/s12902-019-0334-y

Similar Items